Key result
Apixaban proves more cost-effective than other DOACs unless their annual costs drop substantially.
Loading...
Apixaban remains cost-effective at current UK prices; informs formulary choices and price negotiations for other NOACs.
A 2018 study studied atrial fibrillation. Direct acting oral anticoagulants (dabigatran, edoxaban, rivaroxaban) vs. apixaban was evaluated. To be more cost effective than apixaban, annual costs must reduce to £487.86 for dabigatran, £222.93 for edoxaban, and £201.47 for rivaroxaban.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: